cresols

Summary

Top Publications

  1. doi New insights into uremic toxicity
    Amanda C Raff
    Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA
    Curr Opin Nephrol Hypertens 17:560-5. 2008
  2. pmc p-Cresol and cardiovascular risk in mild-to-moderate kidney disease
    Bjorn K I Meijers
    Department of Medicine, Division of Nephrology and Laboratory for Gastro Intestinal Research and Leuven Food Science and Nutrition Research Centre LFoRCe, University Hospital Leuven, Leuven, Belgium
    Clin J Am Soc Nephrol 5:1182-9. 2010
  3. ncbi Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan
    Anna O D'Souza
    Xcenda, LLC, Cincinnati, OH 45255, USA anna dsouza xcenda com
    J Manag Care Pharm 14:291-301. 2008
  4. doi Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial
    Vik Khullar
    St Mary s Hospital, Imperial College, London, UK
    Eur Urol 63:283-95. 2013
  5. doi Erg K+ channels modulate contractile activity in the bovine epididymal duct
    Marco Mewe
    Institute of Vegetative Physiology and Pathophysiology, University Medical Center, Hamburg Eppendorf, Hamburg, Germany
    Am J Physiol Regul Integr Comp Physiol 294:R895-904. 2008
  6. doi Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, Cornell University, New York, NY, USA
    BJU Int 107:1432-40. 2011
  7. doi Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial
    Sender Herschorn
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, Ontario, Canada
    BJU Int 105:58-66. 2010
  8. pmc p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients
    Bjorn K I Meijers
    Department of Medicine, Division of Nephrology, University Hospital Leuven, Leuven, Belgium
    Clin J Am Soc Nephrol 4:1932-8. 2009
  9. pmc p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease
    I Wen Wu
    Department of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan
    Nephrol Dial Transplant 26:938-47. 2011
  10. ncbi Destruction of cresols by Fenton oxidation process
    V Kavitha
    Centre for Environmental Studies, Anna University, Chennai 600 025, India
    Water Res 39:3062-72. 2005

Research Grants

  1. Urodynamic and Multiethnic Variability of Men Treated b*
    Steven Kaplan; Fiscal Year: 2005
  2. Alternative Therapies for BPH, Multiethnic Variablility
    Steven Kaplan; Fiscal Year: 2004
  3. Maximize RAS Blockade in Diabetic Nephropathy
    Timothy Meyer; Fiscal Year: 2003
  4. MECHANISMS OF PROGRESSION IN RENAL INSUFFICIENCY
    Timothy Meyer; Fiscal Year: 2000
  5. Removal of Protein-Bound Solutes by Dialysis
    Timothy Meyer; Fiscal Year: 2007
  6. Mechanisms Progression in Renal Insufficiency
    Timothy Meyer; Fiscal Year: 2006
  7. TRAINING PROGRAM IN ACADEMIC NEPHROLOGY
    Timothy Meyer; Fiscal Year: 2007
  8. Donor Kidney Gene Expression and Delayed Graft Function
    Timothy Meyer; Fiscal Year: 2004
  9. Alternate Therapies for Benign Prostate Symptoms
    Claus Roehrborn; Fiscal Year: 2004
  10. Pelvic Floor Changes Before and After Birth
    Rebecca Rogers; Fiscal Year: 2007

Detail Information

Publications196 found, 100 shown here

  1. doi New insights into uremic toxicity
    Amanda C Raff
    Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA
    Curr Opin Nephrol Hypertens 17:560-5. 2008
    ..New insights into the accumulation of uremic toxins and the loss of function of hormones and enzymes provide important information on the etiology of uremia...
  2. pmc p-Cresol and cardiovascular risk in mild-to-moderate kidney disease
    Bjorn K I Meijers
    Department of Medicine, Division of Nephrology and Laboratory for Gastro Intestinal Research and Leuven Food Science and Nutrition Research Centre LFoRCe, University Hospital Leuven, Leuven, Belgium
    Clin J Am Soc Nephrol 5:1182-9. 2010
    ..It is not known if p-cresol is associated with cardiovascular disease in patients with chronic kidney disease not yet on dialysis...
  3. ncbi Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan
    Anna O D'Souza
    Xcenda, LLC, Cincinnati, OH 45255, USA anna dsouza xcenda com
    J Manag Care Pharm 14:291-301. 2008
    ..No study has compared persistence and adherence to therapy for both the ER and IR versions of tolterodine and oxybutynin...
  4. doi Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial
    Vik Khullar
    St Mary s Hospital, Imperial College, London, UK
    Eur Urol 63:283-95. 2013
    ..Mirabegron, a β(3)-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB)...
  5. doi Erg K+ channels modulate contractile activity in the bovine epididymal duct
    Marco Mewe
    Institute of Vegetative Physiology and Pathophysiology, University Medical Center, Hamburg Eppendorf, Hamburg, Germany
    Am J Physiol Regul Integr Comp Physiol 294:R895-904. 2008
    ..In summary, these data provide strong evidence for a physiological role of erg1 channels in regulating epididymal motility patterns...
  6. doi Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, Cornell University, New York, NY, USA
    BJU Int 107:1432-40. 2011
    ..To show the superior efficacy of fesoterodine over tolterodine extended release (ER) in a placebo-controlled overactive bladder (OAB) trial with predefined treatment comparisons for both diary measures and patient-reported outcomes...
  7. doi Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial
    Sender Herschorn
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, Ontario, Canada
    BJU Int 105:58-66. 2010
    ..To compare the efficacy and tolerability of fesoterodine 8 mg with tolterodine extended-release (ER) 4 mg and placebo in a randomized clinical trial of patients with an overactive bladder (OAB)...
  8. pmc p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients
    Bjorn K I Meijers
    Department of Medicine, Division of Nephrology, University Hospital Leuven, Leuven, Belgium
    Clin J Am Soc Nephrol 4:1932-8. 2009
    ..They share important features such as the albumin-binding site, low dialytic clearance, and both originate from protein fermentation. Whether serum concentrations are related is, however, not known...
  9. pmc p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease
    I Wen Wu
    Department of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan
    Nephrol Dial Transplant 26:938-47. 2011
    ..However, only a few prospective studies have evaluated possible associations between these two retained solutes and renal disease progression in chronic kidney disease (CKD) patients...
  10. ncbi Destruction of cresols by Fenton oxidation process
    V Kavitha
    Centre for Environmental Studies, Anna University, Chennai 600 025, India
    Water Res 39:3062-72. 2005
    The present study was used to probe the treatment of simulated wastewater containing cresols by Fenton process...
  11. doi Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-a-go-go-related gene 1 potassium channel (KCNH2) activator NS1643
    Serdar Durdagi
    Institute for Biocomplexity and Informatics, Department of Biological Sciences, University of Calgary, Calgary, Canada
    J Pharmacol Exp Ther 342:441-52. 2012
    ..Model-guided mutagenesis led to the discovery of a range of novel interacting residues that modify NS1643-induced pharmacologic responses...
  12. ncbi Biodegradation of p-cresol by Bacillus sp. strain PHN 1
    P N Tallur
    Department of Biochemistry, Karnataka University, Dharwad, 580003, India
    Curr Microbiol 53:529-33. 2006
    ..Such a bacterial strain can be used for bioremediation of environments contaminated with phenolic compounds...
  13. ncbi Final report on the safety assessment of sodium p-chloro-m-cresol, p-chloro-m-cresol, chlorothymol, mixed cresols, m-cresol, o-cresol, p-cresol, isopropyl cresols, thymol, o-cymen-5-ol, and carvacrol
    Alan Andersen
    Cosmetic Ingredient Review, Washington, DC 20036, USA
    Int J Toxicol 25:29-127. 2006
    Sodium p-Chloro-m-Cresol, p-Chloro-m-Cresol (PCMC), Mixed Cresols, m-Cresol, o-Cresol, p-Cresol, Isopropyl Cresols, Thymol, Chlorothymol, o-Cymen-5-ol, and Carvacrol are substituted phenols used as cosmetic biocides/preservatives and/or ..
  14. doi Strong activation of ether-à-go-go-related gene 1 K+ channel isoforms by NS1643 in human embryonic kidney 293 and Chinese hamster ovary cells
    Anna M Schuster
    Institute of Cellular and Integrative Physiology, University Medical Center Hamburg Eppendorf UKE, Hamburg, Germany
    Mol Pharmacol 80:930-42. 2011
    ..laevis oocytes...
  15. doi A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability
    Leigh Wellhauser
    Research Institute, Hospital for Sick Children and Departments of Biochemistry and Physiology, University of Toronto, Canada
    Mol Pharmacol 75:1430-8. 2009
    ..These findings suggest that direct binding of this small molecule induces and/or stabilizes a structure that promotes the channel open state and may underlie its efficacy as a corrector of DeltaPhe508-CFTR...
  16. doi Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD3
    Xulin Xu
    Department of Physiology and Biophysics, Virginia Commonwealth University, 1101 E Marshall Street, Richmond, VA 23298, USA
    Mol Pharmacol 73:1709-21. 2008
    ..We suggest that PD may work as a "pore-modifier" of the hERG channel...
  17. pmc Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels
    A P Larsen
    The Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, Copenhagen N, Denmark
    Br J Pharmacol 161:614-28. 2010
    ..1a isoform. In this study, the effects of two different K(v)11.1 activators, NS1643 and RPR260243, were characterized on K(v)11.1a and K(v)11.1b channels...
  18. pmc Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643
    Morten Grunnet
    Department of Drug Discovery Portfolio Management, Neurosearch A S, Pederstrupvej 93, 2750 Ballerup, Denmark
    Mol Pharmacol 79:1-9. 2011
    ....
  19. ncbi Persistence with overactive bladder pharmacotherapy in a Medicaid population
    Fadia T Shaya
    Center on Drugs and Public Policy, University of Maryland School of Pharmacy, Baltimore, USA
    Am J Manag Care 11:S121-9. 2005
    ....
  20. ncbi P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines
    Laetitia Dou
    INSERM EMI0019, Faculte de Pharmacie, Universite de la Mediterranee, and Service de Néphrologie, Hopital de la Conception, Marseille, France
    Kidney Int 62:1999-2009. 2002
    ..We asked whether p-cresol alters endothelial adhesion molecule expression and modifies endothelial/leukocyte adhesion...
  21. ncbi P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production
    Eva Schepers
    Renal Division, Department of Internal Medicine, University Hospital, De Pintelaan 185, 9000 Gent, Belgium
    Nephrol Dial Transplant 22:592-6. 2007
    ..Recently, however, it has been demonstrated that p-cresol in the human body is conjugated, with p-cresylsulphate as the main metabolite...
  22. doi Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease
    Sophie Liabeuf
    INSERM ERI 12 EA 4292 and the Clinical Research Centre Division of Clinical Pharmacology, Amiens University Hospital, Amiens, France
    Nephrol Dial Transplant 25:1183-91. 2010
    ....
  23. ncbi Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene
    Heinz Jungbluth
    Dubowitz Neuromuscular Centre, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Neuromuscul Disord 17:338-45. 2007
    ....
  24. ncbi Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial
    J Malone-Lee
    Department of Medicine, St Pancras Hospital, London, United Kingdom
    J Urol 165:1452-6. 2001
    ..The combination of these qualities makes tolterodine the preferred pharmacological therapy for the long-term treatment of this condition...
  25. doi Free p-cresol is associated with cardiovascular disease in hemodialysis patients
    B K I Meijers
    Division of Nephrology, Department of Medicine, University Hospital Leuven, Leuven, Belgium
    Kidney Int 73:1174-80. 2008
    ..Our study shows that free p-cresol is a novel cardiovascular risk factor in non-diabetic hemodialysis patients...
  26. ncbi P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro
    Claire Cerini
    INSERM EMI0019, Faculte de Pharmacie, Université e la Méditerranée, 27 bld Jean Moulin, 13385 Marseille, Cedex 5, France
    Thromb Haemost 92:140-50. 2004
    ..In conclusion, these results show that p-cresol causes a severe dysfunction of endothelial barrier function in vitro and suggest this uremic retention solute may participate in the endothelium dysfunction observed in CRF patients...
  27. doi The uremic retention solute p-cresyl sulfate and markers of endothelial damage
    Bjorn K I Meijers
    Department of Medicine, Division of Nephrology, University Hospitals Leuven, Leuven, Belgium
    Am J Kidney Dis 54:891-901. 2009
    ..In hemodialysis patients, the protein-bound uremic retention solute p-cresol is independently associated with cardiovascular disease. The underlying mechanisms have not been elucidated...
  28. ncbi A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure
    R De Smet
    Department of Internal Medicine, University Hospital Gent, Belgium
    Clin Chim Acta 278:1-21. 1998
    ..We conclude that the present method allows an accurate measurement of both total and free p-cresol, and that the measured concentrations in uremia are in the range which may cause biochemical alterations...
  29. ncbi Removal of P-cresol sulfate by hemodialysis
    Andres W Martinez
    Department of Medicine, Veterans Association, Palo Alto, California, USA
    J Am Soc Nephrol 16:3430-6. 2005
    ..PCS is poorly removed by hemodialysis because its clearance is limited by protein binding and the ratio of its volume of distribution to its clearance is high...
  30. ncbi Effect of toluene and cresols on Na+,K+-ATPase, and serotonin in rat brain
    David Calderón-Guzmán
    Laboratorio de Neuroquimica, Instituto Nacional de Pediatría INP, Mexico
    Regul Toxicol Pharmacol 41:1-5. 2005
    ..Based in our results, it can be concluded that toluene and all cresols groups may increase lipid peroxidation and consequently induce changes in membrane fluidity.
  31. ncbi Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment
    Linda Brubaker
    Department of Obstetrics, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Urology 68:3-8. 2006
    ..We provide an overview of instruments used to assess symptoms, health-related quality of life, and treatment satisfaction in patients with OAB and discuss how PROs can be incorporated into clinical trial protocols...
  32. ncbi Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder
    Rodney U Anderson
    Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Suite 287, Stanford, CA 94305, USA
    Int Urogynecol J Pelvic Floor Dysfunct 17:502-11. 2006
    ..Discontinuation rates were comparably low across groups. The results demonstrate the appropriateness of initiating treatment for OAB with extended-release oxybutynin, particularly in women presenting with incontinence...
  33. ncbi A throat lozenge containing amyl meta cresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncytial virus, influenza A and SARS-CoV
    John S Oxford
    Retroscreen Virology Ltd, UK
    Antivir Chem Chemother 16:129-34. 2005
    ....
  34. doi Assessing the role of p-cresol tolerance in Clostridium difficile
    Lisa F Dawson
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    J Med Microbiol 57:745-9. 2008
    ..difficile strains including 630, CF4 and CD196. Surprising, it was shown that Clostridium sordellii also has a high tolerance to p-cresol, suggesting an overlap in the tolerance pathways in these clostridial species...
  35. doi Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome
    Thomas G Diness
    Department of Medicine and Research Center, Montreal Heart Institute and Universite de Montreal, 5000 Belanger Street East, Montreal, Quebec, Canada H1T 1C8
    Cardiovasc Res 79:61-9. 2008
    ..This study sought to evaluate the antiarrhythmic effect of a novel compound (NS1643) that activates the rapid delayed-rectifier K+ current, I(Kr), in two rabbit models of acquired LQTS...
  36. ncbi Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system
    A Todorova
    Pro Science Private Research Clinic GmbH, Kurt-Schumacher-Str. 9, D-35440 Linden, Germany
    J Clin Pharmacol 41:636-44. 2001
    ..The minimal qEEG changes observed with tolterodine and trospium chloride reflect most probably a rebound message from the peripheral target organs. Prescription of oxybutynin thus implicates a higher risk of CNS side effects...
  37. doi Factors associated with blood concentrations of indoxyl sulfate and p-cresol in patients undergoing peritoneal dialysis
    Chien Te Lee
    Division of Nephrology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, Taiwan
    Perit Dial Int 30:456-63. 2010
    ..We conducted a cross-sectional study to analyze the factors that correlate with both total and free indoxyl sulfate and p-cresol...
  38. ncbi Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder
    Christopher Chapple
    The Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 52:1204-12. 2007
    ..To determine the efficacy, tolerability, and safety of fesoterodine in subjects with overactive bladder (OAB)...
  39. ncbi Activation of ERG2 potassium channels by the diphenylurea NS1643
    Pernille Elmedyb
    The Danish National Research Foundation Centre for Cardiac Arrhythmia, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Neuropharmacology 53:283-94. 2007
    ..It may be useful for revealing physiological functions of ERG channels in neuronal tissue as well as to elucidate the structure-function relationships of the ERG channels...
  40. ncbi Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial
    Y Homma
    Department of Urology, Tokyo University Hospital, 7 3 1 Hongo Bunkyo ku, 113 8655 Tokyo, Japan
    World J Urol 22:251-6. 2004
    ..Our findings demonstrate that Japanese OAB patients receiving tolterodine ER or oxybutynin experienced overall improvement in their quality of life...
  41. ncbi Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial
    Vik Khullar
    Department of Obstetrics and Gynaecology, Imperial College School of Medicine, London, United Kingdom
    Urology 64:269-74; discussion 274-5. 2004
    ..To examine the efficacy and tolerability of antimuscarinic therapy in women with urge-predominant mixed incontinence...
  42. ncbi Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways
    YongTae Kim
    Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Urology 65:238-42. 2005
    ..To investigate the potential of antimuscarinic agents for sensory mechanisms in overactive bladder using intravesical instillation...
  43. doi Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome
    Ling Hong Tseng
    Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital and University of Chang Gung School of Medicine, Tao Yuan, Taiwan
    Neurourol Urodyn 28:47-51. 2009
    ..To investigate whether vaginal estrogen cream combined with tolterodine is more effective than tolterodine alone in the treatment of postmenopausal women with overactive bladder (OAB)...
  44. ncbi Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder
    Martin C Michel
    Department of Pharmacology and Pharmacotherapy, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
    Eur Urol 48:110-5. 2005
    ..Therefore, we have explored baseline symptoms and treatment responses to tolterodine in continent relative to incontinent OAB patients...
  45. ncbi Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA
    JAMA 296:2319-28. 2006
    ..Men with overactive bladder and other lower urinary tract symptoms may not respond to monotherapy with antimuscarinic agents or alpha-receptor antagonists...
  46. ncbi A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial
    C R Chapple
    Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust, Urology Research, South Yorkshire, UK
    Eur Urol 48:464-70. 2005
    ..To compare two new generation antimuscarinics at their recommended doses for treatment of overactive bladder syndrome (OAB)...
  47. doi Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine
    K S Coyne
    Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD 20814, USA
    Int J Clin Pract 62:925-31. 2008
    ..Relationships were evaluated between treatment-related improvements in overactive bladder (OAB) symptoms as recorded in bladder diaries and patient-reported symptom bother, bladder-related problems and health-related quality of life (HRQL)...
  48. ncbi Validation of the urgency perception scale
    Linda Cardozo
    Urogynaecology, Kings College Hospital, London, UK
    BJU Int 95:591-6. 2005
    ..To ascertain the validity and responsiveness of the Urgency Perception Scale (UPS) as an indicator of perceived urinary urgency...
  49. pmc Mechanism of action of a novel human ether-a-go-go-related gene channel activator
    Oscar Casis
    Nora Eccles Harrison Cardiovascular Research and Training Institute and Department of Physiology, University of Utah, Salt Lake City, 84112, USA
    Mol Pharmacol 69:658-65. 2006
    ..We conclude that NS1643 is a partial agonist of hERG channels and that the mechanism of activation is reduced channel inactivation...
  50. ncbi Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients
    B Bammens
    Department of Medicine, Division of Nephrology, University Hospital Gasthuisberg, Leuven, Belgium
    Kidney Int 69:1081-7. 2006
    ..These findings may encourage nephrologists to widen their field of interest beyond the scope of small water-soluble uremic solutes and middle molecules...
  51. ncbi Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia
    Raymond Rackley
    Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
    Urology 67:731-6; discussion 736. 2006
    ..To evaluate the efficacy and tolerability of nighttime tolterodine dosing on urgency-related micturitions in patients with overactive bladder (OAB) and nocturia...
  52. ncbi Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy
    Maurizio Serati
    Department of Obstetrics and Gynecology, University of Insubria, Del Ponte Hospital, Piazza Biroldi 1, Varese, Italy
    Eur Urol 54:911-5. 2008
    ..To understand the pathophysiological mechanism of incontinence during orgasm and to compare women affected by symptomatic detrusor overactivity (DO) with and without incontinence at orgasm in terms of efficacy of antimuscarinic treatment...
  53. ncbi Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial
    R Roberts
    University of Wisconsin School of Medicine and Public Health, Madison, USA
    Int J Clin Pract 60:752-8. 2006
    ..Physicians reported that 68% of patients were 'much improved' or 'very much improved'. For symptom-defined conditions, patient-reported outcomes are a valuable means for determining responses to treatment...
  54. ncbi Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643)
    Rie Schultz Hansen
    Neurosearch A S, Pederstrupvej 93, 2750 Ballerup, Denmark
    Mol Pharmacol 69:266-77. 2006
    ..In conclusion, HERG channel activation by small molecules such as NS1643 increases the repolarization reserve and presents an interesting new antiarrhythmic approach...
  55. ncbi The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair
    Laetitia Dou
    INSERM EMI0019, UFR de Pharmacie, Universite de la Mediterranee, Marseille, France
    Kidney Int 65:442-51. 2004
    ..In addition, we tested the effect of uremic solutes that altered proliferation on endothelial wound repair...
  56. ncbi Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence
    Roger R Dmochowski
    Department of Urology, Vanderbilt University, Nashville, Tennessee, USA
    Urology 62:237-42. 2003
    ..To compare the efficacy and safety of an oxybutynin transdermal delivery system (OXY-TDS) and oral, long-acting tolterodine (TOL-LA) with placebo in previously treated patients with urge or mixed urinary incontinence...
  57. ncbi Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial
    Y Homma
    Department of Urology, Tokyo University, Tokyo, Japan
    BJU Int 92:741-7. 2003
    ..To compare extended-release (ER) tolterodine and immediate-release (IR) oxybutynin with placebo in Japanese and Korean patients with an overactive bladder (OAB)...
  58. ncbi Tolterodine: a safe and effective treatment for older patients with overactive bladder
    J G Malone-Lee
    Department of Medicine, Whittington Hospital, Royal Free and University College Medical School, London, Great Britain
    J Am Geriatr Soc 49:700-5. 2001
    ..CONCLUSION: Tolterodine (taken for 4 weeks) is safe and shows efficacy, particularly at a dosage of 2 mg bid, in the treatment of older patients with urinary symptoms attributable to overactive bladder...
  59. ncbi Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study
    R A Appell
    Cleveland Clinic Foundation, Ohio, USA
    Mayo Clin Proc 76:358-63. 2001
    ..To compare the efficacy and tolerability of extended-release oxybutynin chloride and tolterodine tartrate at 12 weeks in participants with overactive bladder...
  60. ncbi Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine
    Robert Freeman
    Urogynaecology Unit, Derriford Hospital, Plymouth, United Kingdom
    Obstet Gynecol 102:605-11. 2003
    ..To evaluate the effect of once-daily, extended-release tolterodine on urinary urgency in patients with overactive bladder...
  61. ncbi Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder
    H P Drutz
    University of Toronto, Mount Sinai Hospital, Ontario, Canada
    Int Urogynecol J Pelvic Floor Dysfunct 10:283-9. 1999
    ..Tolterodine has equivalent efficacy to oxybutynin, but with less severe adverse effects. This will allow patients to receive more effective treatment for their condition, with better compliance...
  62. ncbi Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder
    P Van Kerrebroeck
    Department of Urology, University Hospital Maastricht, Maastricht, The Netherlands
    Urology 57:414-21. 2001
    ..Tolterodine ER demonstrated an improved efficacy for reducing urge incontinence episodes and a lower frequency of dry mouth compared with the existing IR twice-daily formulation...
  63. ncbi Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder
    Con J Kelleher
    Guy s and St Thomas NHS Trust, London, United Kingdom
    Am J Manag Care 8:S608-15. 2002
    ..To compare the health-related quality of life (HRQoL) of overactive bladder (OAB) patients foilowing treatment with tolterodine extended-release (ER) 4 mg once daily versus placebo...
  64. ncbi Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder
    Con J Kelleher
    Guy s and St Thomas NHS Trust, London, United Kingdom
    Am J Manag Care 8:S616-30. 2002
    ..To evaluate the long-term effects of tolterodine on the health-related quality of life (HRQoL) of patients diagnosed with overactive bladder with incontinence...
  65. ncbi Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder
    A Mattiasson
    Department of Urology, University Hospital, Lund, Sweden
    BJU Int 91:54-60. 2003
    ..To compare the efficacy of tolterodine plus simplified bladder training (BT) with tolterodine alone in patients with an overactive bladder...
  66. ncbi Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET)
    David Sussman
    Department of Surgery, University of Medicine and Dentistry of New Jersey, Stratford 08084, USA
    Curr Med Res Opin 18:177-84. 2002
    ..In conclusion, the greater efficacy and tolerability of tolterodine ER 4 mg suggests improved clinical effectiveness compared with oxybutynin ER 10 mg...
  67. ncbi Identification of a key determinant of ryanodine receptor type 1 required for activation by 4-chloro-m-cresol
    James D Fessenden
    Department of Anesthesia Research, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 278:28727-35. 2003
    ..Taken together, these results suggest that essential determinants required for activation of RyR1 by 4-CmC reside within a 173-amino acid region between residues 4007 and 4180...
  68. ncbi Tolterodine and memory: dry but forgetful
    Kyle B Womack
    Department of Neurology, University of Florida College of Medicine, and the Neurology Service, Department of Veterans Affairs Medical Center, Gainesville, USA
    Arch Neurol 60:771-3. 2003
    ..Anticholinergic drugs are known to produce or enhance cognitive deficits. Tolterodine tartrate is marketed as a bladder-selective anticholinergic drug that is reported to be free of significant cognitive adverse effects...
  69. ncbi Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial
    Ananias C Diokno
    Department of Urology, William Beaumont Hospital, Royal Oak, Mich 48073, USA
    Mayo Clin Proc 78:687-95. 2003
    ..To compare the efficacy and tolerability of extended-release formulations of oxybutynin chloride and tolterodine tartrate in women with overactive bladder...
  70. ncbi Transient memory impairment and hallucinations associated with tolterodine use
    Jack W Tsao
    N Engl J Med 349:2274-5. 2003
  71. ncbi Does gender or age affect the efficacy and safety of tolterodine?
    Martin C Michel
    Department of Medicine, University of Essen, Essen, Germany
    J Urol 168:1027-31. 2002
    ..We compared the importance of patient age and gender relative to the intensity of baseline symptoms of overactive bladder in the therapeutic response to the muscarinic receptor antagonist tolterodine...
  72. ncbi Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder
    C R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 93:303-10. 2004
    ..e. urgency, incontinence, and frequency, with additional objectives being to assess the safety and tolerability of solifenacin and to compare the efficacy and safety of solifenacin with tolterodine 2 mg twice daily...
  73. ncbi p-Hydroxyphenylacetate decarboxylase from Clostridium difficile. A novel glycyl radical enzyme catalysing the formation of p-cresol
    T Selmer
    Laboratorium für Mikrobiologie, Fachbereich Biologie, Philipps Universitat, Marburg, Germany
    Eur J Biochem 268:1363-72. 2001
    ..Based on the identification of p-hydroxyphenylacetate decarboxylase as a novel glycyl radical enzyme and the substrate specificity of the enzyme, a catalytic mechanism involving ketyl radicals as intermediates is proposed...
  74. ncbi The responsiveness of the Overactive Bladder Questionnaire (OAB-q)
    Karin S Coyne
    MEDTAP International, Inc, Center for Health Outcomes Research, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    Qual Life Res 14:849-55. 2005
    ..The purpose of this study was to examine the responsiveness of the Overactive Bladder questionnaire (OAB-q) during anti-muscarinic treatment...
  75. ncbi Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen
    R J Millard
    University of New South Wales, Sydney, Australia
    Neurourol Urodyn 23:48-53. 2004
    ....
  76. ncbi Treatment of phenol and cresols in upflow anaerobic sludge blanket (UASB) process: a review
    Gali S Veeresh
    Department of Civil Engineering, Indian Institute of Technology Roorkee, Roorkee 247667, India
    Water Res 39:154-70. 2005
    ..recognition of the UASB process, feasibility studies on the treatment of wastewater containing phenol and cresols (o-, m- and p- isomers) in UASB have been reviewed...
  77. ncbi Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients
    Norman R Zinner
    Doctors Urology Group, Torrance, California 90505, USA
    J Am Geriatr Soc 50:799-807. 2002
    ..To evaluate the efficacy, safety, and tolerability of a new, once-daily extended-release (ER) formulation of tolterodine in treating overactive bladder in older (> or =65) and younger (<65) patients...
  78. ncbi Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum
    Henriette de Loor
    Department of Medicine, University Hospital Gasthuisberg K U Leuven, Leuven, Belgium
    Clin Chem 51:1535-8. 2005
  79. ncbi Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity
    YongTae Kim
    Department of Urology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA
    BJU Int 97:400-3. 2006
    ..To study the effects of antimuscarinics excreted into human urine on normal bladder in a rat model of detrusor overactivity...
  80. ncbi The emergence of new drugs for overactive bladder
    Rebecca J McCrery
    Division of Voiding Dysfunction and Female Urology, Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
    Expert Opin Emerg Drugs 11:125-36. 2006
    ..Standard therapy is directed towards modifying the detrusor motor sensitivity and response via anticholinergic medication. Currently available medications are reviewed and alternative targets for treatment are presented...
  81. pmc Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions
    Patrizia Angelico
    Pharmaceutical R and D Division, RECORDATI S p A, Via Civitali 1, 20148 Milan, Italy
    BMC Pharmacol 5:14. 2005
    ..The aim was to determine the experimental conditions required to reproduce the clinical pharmacological effects of antimuscarinic agents, as seen in humans, in particular their ability to increase bladder capacity...
  82. ncbi Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study
    A Agarwal
    Department of Anaesthesia, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
    Br J Anaesth 96:377-80. 2006
    ..This study was therefore undertaken to evaluate the efficacy of oxybutynin and tolterodine in preventing catheter related bladder discomfort...
  83. ncbi Tolterodine: a clinical review
    C Crandall
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095-7023, USA
    J Womens Health Gend Based Med 10:735-43. 2001
    ..In all randomized controlled trials to date, tolterodine 2 mg bid is an equally effective alternative to oxybutynin 5 mg tid, while causing less intense and less frequent dry mouth or need for treatment withdrawal...
  84. ncbi [Urinary incontinence--treatment]
    C Hader
    Zentrum fur Innere Medizin, Kliniken St Antonius, Wuppertal
    Dtsch Med Wochenschr 128:750-2. 2003
  85. pmc Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial
    Dexter Y L Leung
    Br J Clin Pharmacol 60:668; author reply 669. 2005
  86. ncbi Bladder-health diaries: an assessment of 3-day vs 7-day entries
    Roger R Dmochowski
    Department of Urologic Surgery, Vanderbilt University Medical Center, 2201 West End Avenue, Nashville, TN 37235, USA
    BJU Int 96:1049-54. 2005
    ..To assess the reliability of symptom reports in 3-day vs 7-day bladder diaries used in clinical trials of patients with overactive bladder (OAB) and to compare those results and related issues with previous reports...
  87. ncbi Contemporary treatment options for overactive bladder
    Paul H Taylor
    Department of Family and Preventive Medicine, Emory University, Atlanta, Georgia, USA
    JAAPA . 2005
  88. ncbi Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations
    Denis Getsios
    Caro Research Institute, Halifax, Nova Scotia, Canada
    Pharmacoeconomics 23:995-1006. 2005
    ..A more definitive pharmacoeconomic comparison of oxybutynin and tolterodine formulations, incorporating all available clinical data, and other treatment options would help direct treatment...
  89. doi Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder
    Eric S Rovner
    Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas St, CSB 644, Charleston, SC 29425, USA
    Urology 72:488-93. 2008
    ..To assess efficacy and tolerability of tolterodine extended release (ER) in continent and incontinent subjects with overactive bladder (OAB)...
  90. ncbi Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder
    Susan C Bolge
    Consumer Health Sciences, Princeton, NJ 08540, USA
    Curr Med Res Opin 23:1903-12. 2007
    ..To evaluate the effects of individual and condition characteristics on satisfaction with extended release tolterodine or oxybutynin in overactive bladder (OAB)...
  91. ncbi The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder
    Roger Dmochowski
    Department of Urology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    BJU Int 100:107-10. 2007
    ..To assess the 24-h efficacy of tolterodine extended-release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI)...
  92. ncbi Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials
    Robert B Armstrong
    Ortho McNeil Neurologics, Inc, 1125 Trenton Harbourton Road, Titusville, NJ 08560 0200, USA
    Int Urol Nephrol 39:1069-77. 2007
    ..In total, 1.2, 1.0, and 1.6% of patients in the extended-release oxybutynin, extended-release tolterodine, and immediate-release tolterodine groups, respectively, discontinued study medication due to dry mouth...
  93. ncbi Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review
    Eric S Rovner
    Division of Urology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Eur Urol 41:6-14. 2002
    ..Overall, available clinical data suggest that the newly developed ER formulation of tolterodine represents a significant therapeutic advancement in the treatment of OAB...
  94. ncbi Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin
    Zhanna Jumadilova
    Outcomes Research, Pfizer Inc, New York, NY 10017 5755, USA
    Am J Health Syst Pharm 63:2357-64. 2006
    ..The frequency, relative risk, resource utilization, and costs related to comorbidities associated with overactive bladder (OAB) were studied...
  95. ncbi The newer antimuscarinic drugs: bladder control with less dry mouth
    Rodney A Appell
    Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Cleve Clin J Med 69:761, 765-6, 768-9. 2002
    ..I review clinical trial data on the newer agents...
  96. ncbi Treatment can lead to a long dry spell
    Cynthia H Starr
    Bus Health . 2002
  97. ncbi Achieving bladder control. Treatment in the primary care setting
    Cynthia M Maloney
    Seton Health Incontinence Treatment Center, Troy, N Y, USA
    Adv Nurse Pract 10:73-8. 2002
  98. ncbi The latest in treatments for incontinence in women
    Joyce Hinze
    Nebr Nurse 39:22-6; quiz 27-8. 2006
  99. ncbi A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder
    S Swift
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
    Int Urogynecol J Pelvic Floor Dysfunct 14:50-4; discussion 54-5. 2003
    ..There were no safety concerns. Toltrodine ER 4 mg once daily is effective and well tolerated in the treatment of women with overactive bladder, and reduces urge incontinence episodes more than the existing IR twice-daily formulation...
  100. ncbi Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence
    Claus G Roehrborn
    The University of Texas Southwestern Medical Center, Dallas, TX 75390 911, USA
    BJU Int 97:1003-6. 2006
    ..They found that it significantly reduced incontinent episodes and improved patient perception of treatment benefit in men with an overactive bladder..
  101. ncbi Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability
    Nizamettin Kilic
    The Medical Faculty of Uludag University, Department of Paediatric Surgery, Bursa, Turkey
    Int J Urol 13:105-8. 2006
    ..The aim of this study is to assess the effectiveness and tolerability of tolterodine and oxybutynin in children with DI...

Research Grants99

  1. Urodynamic and Multiethnic Variability of Men Treated b*
    Steven Kaplan; Fiscal Year: 2005
    ..Baseline urodynamic parameters which may predict improved outcome after MIST 3. The success of various types of MIST in treating BPH in African - American, Hispanic and Caucasian men. ..
  2. Alternative Therapies for BPH, Multiethnic Variablility
    Steven Kaplan; Fiscal Year: 2004
    ..forms of BPH resulting in different rates of progression and differential response to therapy? and, D) whether concomitant prostate conditions such as prostatitis are effected by phytotherapeutic intervention for BPH? ..
  3. Maximize RAS Blockade in Diabetic Nephropathy
    Timothy Meyer; Fiscal Year: 2003
    ..But the number of such trials which can be performed is limited. Short term trials, such as those described in this proposal, are urgently required to help identify treatment regimens which merit further, longer term study. ..
  4. MECHANISMS OF PROGRESSION IN RENAL INSUFFICIENCY
    Timothy Meyer; Fiscal Year: 2000
    ..It is anticipated that with a better understanding of when and how AII contributes to the progression of renal disease, it will be feasible to more rationally prescribe AII antagonist therapy. ..
  5. Removal of Protein-Bound Solutes by Dialysis
    Timothy Meyer; Fiscal Year: 2007
    ..The proposed ancillary study to the FHN will provide a unique opportunity to relate protein-bound solute levels to other chemical parameters and indices of well-being in a large group of hemodialysis patients. ..
  6. Mechanisms Progression in Renal Insufficiency
    Timothy Meyer; Fiscal Year: 2006
    ..These studies, like those of endocytosis, will employ knockout mice to assess the importance of potential mediators of injury which are not yet subject to pharmacologic manipulation. ..
  7. TRAINING PROGRAM IN ACADEMIC NEPHROLOGY
    Timothy Meyer; Fiscal Year: 2007
    ..At the Veterans Affairs Palo Alto Health Care System there are well-equipped research laboratories in the Medical Service that have been assigned to the Nephrology Division. ..
  8. Donor Kidney Gene Expression and Delayed Graft Function
    Timothy Meyer; Fiscal Year: 2004
    ..Ultimately, better understanding of these mechanisms should provide a basis for treatment to prevent cadaver kidney injury and improve graft function. ..
  9. Alternate Therapies for Benign Prostate Symptoms
    Claus Roehrborn; Fiscal Year: 2004
    ..8) Determine whether saw palmetto or pygeum africanum compared to placebo induce measurable changes in prostate volume, transition zone volume, serum PSA and other serum or tissue based biomarkers of BPH. ..
  10. Pelvic Floor Changes Before and After Birth
    Rebecca Rogers; Fiscal Year: 2007
    ..This project will provide fundamental data to guide future decisions about labor interventions to prevent PF changes as well as data-based decisions regarding maternal request cesarean. ..
  11. Minimally Invasive Surgical Therapies Treatment Consort*
    Claus Roehrborn; Fiscal Year: 2005
    ..The MIST Study Group will be a blueprint for a technology assessment group applicable to other areas of urology and other medical or surgical subspecialties. ..
  12. Pelvic Floor Changes Before and After Birth
    REBECCA GLENN ROGERS; Fiscal Year: 2010
    ..This project will provide fundamental data to guide future decisions about labor interventions to prevent PF changes as well as data-based decisions regarding maternal request cesarean. ..
  13. Pelvic Floor Changes Before and After Birth
    REBECCA GLENN ROGERS; Fiscal Year: 2010
    ..This project will provide fundamental data to guide future decisions about labor interventions to prevent PF changes as well as data-based decisions regarding maternal request cesarean. ..
  14. Alternative Therapies for Benign Prostate Symptoms
    Karl Kreder; Fiscal Year: 2007
    ....
  15. Interstitial Cystitis Clinical Research Network (ICCRN)
    Karl Kreder; Fiscal Year: 2007
    ..abstract_text> ..
  16. Pathophysiology of Anorectal Disorders
    Adil Bharucha; Fiscal Year: 2009
    ..This proposal will enhance our understanding of the mechanisms and assess novel approaches to manage FI. ..
  17. Patient-Oriented Models for Urinary Function in Women
    Linda Brubaker; Fiscal Year: 2007
    ..b. To model urinary storage in health and disease c. To model urinary emptying in health and diseas ..
  18. Pathophysiology of Anorectal Disorders
    Adil E Bharucha; Fiscal Year: 2010
    ..This proposal will enhance our understanding of the mechanisms and assess novel approaches to manage FI. ..
  19. Continuation of the Urinary Incontinence Treatment Network (UITN)
    Linda Brubaker; Fiscal Year: 2007
    ..We believe that we can continue to be a productive member of the UITN, with the ultimate objective of improving quality of life for adults through the conduct of high impact clinical research in urinary incontinence. ..
  20. The Pelvic Floor Disorders Network
    Linda Brubaker; Fiscal Year: 2007
    ..vaginal) is best suited for an individual woman. This trial is a feasible, scientifically relevant randomized surgical trial. The draft protocol is suitable for PFDN Steering Committee discussion and revision, prior to implementation. ..
  21. ANORECTAL MANIFESTATIONS OF FEMALE PELVIC FLOOR DISORDER
    Adil Bharucha; Fiscal Year: 2002
    ..abstract_text> ..
  22. Iowa Pelvic Floor Disorders Clinical Trials Network
    Karl Kreder; Fiscal Year: 2005
    ..abstract_text> ..
  23. ADVANCED POP AND THE URINARY CONTINENCE MECHANISM
    Linda Brubaker; Fiscal Year: 2004
    ..abstract_text> ..
  24. Epidemiology and Mechanisms of Fecal Incontinence
    Adil Bharucha; Fiscal Year: 2005
    ..abstract_text> ..
  25. TRAINING IN UROLOGY
    Alan Wein; Fiscal Year: 2003
    ..At each step the trainees will be advised by experienced investigators. It is expected that in return the clinician's will offer to the laboratory insight into the fundamental clinical problems facing the specialty of urology. ..
  26. Sensory Testing in Subjects with Interstitial Cystitis
    Mary FitzGerald; Fiscal Year: 2004
    ..abstract_text> ..
  27. Radiological Biomarkers for Frontotemporal Lobar Degeneration
    Kyle Womack; Fiscal Year: 2007
    ..Furthermore, a biomarker of disease progression may improve the power of relatively small, brief therapeutic trials. ..
  28. Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome
    James Baraniuk; Fiscal Year: 2009
    ..These methods and biomarkers may be of diagnostic value. They will be useful for assessing longitudinal changes in disease severity, phenotype, or the effects of treatment. ..
  29. Molecular mechanisms of RyR activation by 4-CmC
    JAMES FESSENDEN; Fiscal Year: 2007
    ..abstract_text> ..
  30. Safety and Efficacy of Nerve Rerouting for Treating Neurogenic Bladder in Spina B
    Kenneth M Peters; Fiscal Year: 2010
    ..Dr. Xiao, in China, developed a new procedure to rewire the nerves affecting the bladder, and this project aims to scientifically establish the safety and effectiveness of the surgical procedure. ..
  31. PHYSICIAN AND SCIENTIST TRAINING IN UROLOGICAL RESEARCH
    Alan Wein; Fiscal Year: 2007
    ..Funding is sought for two years of support for three trainees annually. ..
  32. BOTULINUM TOXIN THERAPY FOR INTERSTITIAL CYSTITIS/CHRON*
    Mary FitzGerald; Fiscal Year: 2007
    ..abstract_text> ..
  33. Regulation of Bladder Smooth Muscle Hyperplasia
    Paul Austin; Fiscal Year: 2007
    ..Work of this nature may decrease the morbidity and mortality that is caused by bladder outlet obstruction. ..
  34. Clinical Trial Development in Chronic Pelvic Pain Syndr*
    Daniel Shoskes; Fiscal Year: 2007
    ..As an example of a potential clinical trial, a study of water induced thermotherapy is outlined. ..
  35. MECHANISMS OF RHINITIS IN CFS
    James Baraniuk; Fiscal Year: 1999
    ..e. nasal provocation) as the means to evaluate future treatments of CFS. ..
  36. Chronic Prostatitis Collaborative Research Network
    Rodney Anderson; Fiscal Year: 2007
    ..abstract_text> ..
  37. The Role of NK-Kb signaling pathway--Intestitial Cystits
    Raymond Rackley; Fiscal Year: 2004
    ....
  38. Beaumont Interstitial Cystitis Clinical Research Network
    Kenneth Peters; Fiscal Year: 2007
    ..Adverse events and complications will be monitored. Ancillary studies as agreed upon by the ICCRN will be carried out in conjunction with the clinical trial. ..
  39. Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome
    James Baraniuk; Fiscal Year: 2007
    ..These methods and biomarkers may be of diagnostic value. They will be useful for assessing longitudinal changes in disease severity, phenotype, or the effects of treatment. ..
  40. Chronic Prostatitis Collaborative Research Network
    Rodney Anderson; Fiscal Year: 2007
    ..abstract_text> ..